SETD4 and cholangiocarcinoma: Based on the results, SETD4 was upregulated in multiple human malignancies, including bladder urothelial carcinoma (BLCA), lung adenocarcinoma (LUAD), cholangiocarcinoma (CHOL), head and neck squamous cell carcinoma (HNSC), esophageal carcinoma (ESCA), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), kidney renal papillary cell carcinoma (KIRP), rectum adenocarcinoma (READ), and stomach adenocarcinoma (STAD).